In this article, we will list the 5 Undervalued Counter Cyclical Stocks to Buy Now. Please visit 10 Undervalued Counter Cyclical Stocks to Buy Now if you would like to see the extended list and the methodology behind it.
5. Equinox Gold Corp. (NYSEAMERICAN:EQX)
On June 8, 2026, RBC Capital lowered the firm’s price target on Equinox Gold Corp. (NYSEAMERICAN:EQX) to $14 from $17 and maintained an Outperform rating on the shares. RBC said scale, high growth, and geographic exposure have been key aspects of the company’s ORLA deal. The firm added that, compared with its positive first impressions of the transaction, its view is now more balanced, with a more mixed valuation implication.
On May 13, 2026, Equinox Gold Corp. (NYSEAMERICAN:EQX) and Orla Mining (ORLA) announced a definitive arrangement agreement for an at-market combination to create a new North American senior gold producer. The combined company is expected to have approximately 1.1M ounces of annual gold production and an $18.5B implied market capitalization. Equinox will acquire all issued and outstanding common shares of Orla, and the combined company will continue under the name Equinox Gold Corp.
Meanwhile, on May 14, 2026, Stifel raised the firm’s price target on Equinox Gold Corp. (NYSEAMERICAN:EQX) to C$35 from C$31 and maintained a Buy rating on the shares.
Earlier in May, Equinox Gold reported Q1 adjusted EPS of 40c, compared with consensus of 29c, and revenue of $861.6M, compared with consensus of $865.91M. CEO Darren Hall said the company produced 197,628 ounces of gold during the quarter, with cash costs of $1,633 per oz and all-in sustaining costs of $1,950 per oz.
Equinox Gold Corp. (NYSEAMERICAN:EQX) acquires, explores, develops, and operates mineral properties in the Americas.
4. AbbVie Inc. (NYSE:ABBV)
On June 12, 2026, AbbVie Inc. (NYSE:ABBV) announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association 2026 Congress in Stockholm, Sweden. Final results from the Phase 3 CLL14 trial in previously untreated chronic lymphocytic leukemia showed that venetoclax plus obinutuzumab significantly improved progression-free survival compared with chlorambucil plus obinutuzumab. After a median follow-up of 9.2 years, median progression-free survival was 6.4 years for venetoclax plus obinutuzumab versus 3.2 years for obinutuzumab plus chlorambucil.
On May 29, 2026, AbbVie Inc. (NYSE:ABBV) announced that the European Commission authorized an expanded label for Venclyxto to include use in combination with acalabrutinib and with ibrutinib for adult patients with previously untreated chronic lymphocytic leukemia. AbbVie said the all-oral, fixed-duration combination regimens support current standards of care and provide additional targeted oral medication options in the first-line setting, including the potential for time off treatment. The authorization extends to European Union Member States, as well as Iceland, Norway, and Liechtenstein.
On May 27, 2026, AbbVie Inc. (NYSE:ABBV) announced that the FDA approved DECNUPAZ, or pivekimab sunirine-pvzy, for adult patients with BPDCN, an ultra-rare and aggressive hematologic malignancy with limited treatment options. The approval was supported by data from the Phase 1/2 CADENZA trial. In newly diagnosed BPDCN patients, DECNUPAZ showed a composite complete response rate of 69.7% with a median duration of response of 9.7 months, while relapsed or refractory patients had a composite complete response rate of 15.7% with a median duration of response of 9.2 months.
AbbVie Inc. (NYSE:ABBV) researches, develops, manufactures, commercializes, and sells medicines and therapies worldwide.
3. Gilead Sciences, Inc. (NASDAQ:GILD)
On June 12, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) announced a donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to support response efforts for the current outbreak of Ebola Bundibugyo virus disease. Anu Osinusi, Vice President of Clinical Development, Virology at Gilead Sciences, said the company recognizes the urgency of global health emergencies and is working with partners to support the outbreak response.
On June 8, 2026, Merck (MRK) and Gilead Sciences, Inc. (NASDAQ:GILD) announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study evaluating Trodelvy in combination with KEYTRUDA, compared with KEYTRUDA monotherapy, in certain patients with previously untreated metastatic non-small cell lung cancer whose tumors expressed PD-L1. The decision followed a recommendation from the external Data Monitoring Committee after its review of the pre-specified final analysis of progression-free survival and interim analysis of overall survival. The companies said a numerical improvement in progression-free survival was observed, but did not reach statistical significance, while the probability of achieving statistically significant overall survival at the planned final analysis was unlikely.
On June 2, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) announced Phase 3 results in primary biliary cholangitis showing that Livdelzi led to significantly more patients achieving normalization of alkaline phosphatase, or ALP, compared with placebo after 52 weeks. The primary endpoint was defined as ALP less than or equal to 1.0 upper limit of normal and a greater than or equal to 15% decrease from baseline. Cynthia Levy of the University of Miami Miller School of Medicine said the IDEAL results further support the efficacy and safety profile of Livdelzi and extend its evidence base to a broader population of people living with PBC.
Gilead Sciences, Inc. (NASDAQ:GILD) discovers, develops, and commercializes medicines in areas of unmet medical need in the United States, Europe, and internationally.
2. Tenet Healthcare Corporation (NYSE:THC)
On June 9, 2026, BofA lowered the firm’s price target on Tenet Healthcare Corporation (NYSE:THC) to $210 from $230 and maintained a Buy rating on the shares. BofA said it was lowering price targets for several hospital names because of lower multiples tied to the generally weak utilization backdrop.
Last month, Barclays analyst Andrew Mok lowered the firm’s price target on Tenet Healthcare Corporation (NYSE:THC) to $238 from $257 and maintained an Overweight rating on the shares following the Q1 report. Mok said Tenet “exhibited its ability to flex the acute cost structure” despite volume headwinds. Morgan Stanley also lowered the firm’s price target on Tenet to $254 from $260 and maintained an Overweight rating, saying the company’s consistent execution was evident in Q1, where EBITDA beat by 3.5% despite industry headwinds.
Earlier, Tenet Healthcare Corporation (NYSE:THC) reported Q1 adjusted EPS of $4.82, compared with consensus of $4.17, and revenue of $5.37B, compared with consensus of $5.4B. CEO Saum Sutaria said the company delivered strong results in both the Ambulatory and Hospital segments, supported by disciplined operations and strong free cash flow. Sutaria also said Tenet continues to support physician partners as it executes on its high acuity strategy and grows organically and inorganically.
Tenet Healthcare Corporation (NYSE:THC) operates as a diversified healthcare services company in the United States.
1. Keurig Dr Pepper Inc. (NASDAQ:KDP)
On June 11, 2026, Bernstein initiated coverage of Keurig Dr Pepper Inc. (NASDAQ:KDP) with an Outperform rating and $38 price target. The firm said Keurig Dr Pepper has an “outstanding” functional beverages portfolio and, while the company is in the middle of “a challenging integration rife with risk,” it believes those risks are well understood and priced in. Bernstein also said beverages should continue to outperform and drive appreciation.
Also on June 11, JAB BevCo B.V., a subsidiary of JAB Holding Company, announced that it sold its remaining stake in Keurig Dr Pepper Inc. (NASDAQ:KDP). The stake consisted of approximately 59.1M shares, or about 4.3% of KDP’s outstanding common stock, and was sold through an unregistered block trade by J.P. Morgan Securities (JPM). JAB said it remains committed to its consumer investment platform and will continue focusing on building resilient consumer businesses.
Earlier, Keurig Dr Pepper Inc. (NASDAQ:KDP) reported Q1 adjusted EPS of 39c, compared with consensus of 37c, and revenue of $3.98B, compared with consensus of $3.83B. CEO Tim Cofer said the company delivered a solid first quarter, with strong momentum in its cold beverage portfolio and coffee results that tracked with expectations. Cofer also said Keurig Dr Pepper completed its acquisition of JDE Peet’s earlier in the month, marking a milestone in its transformation agenda.
Keurig Dr Pepper Inc. (NASDAQ:KDP) owns, manufactures, and distributes beverages and single-serve brewing systems in the United States and internationally.
While we acknowledge the potential of KDP to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than KDP and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 15 High Growth Stocks to Buy and Hold for the Next Decade and 12 Strong Buy Stocks to Buy and Hold for the Next 5 Years
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
Hedge Fund Resource Center